Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

Kenneth B. Jonsson, Richard Zahradnik, Tobias Larsson, Kenneth E. White, Toshitsugu Sugimoto, Yasuo Imanishi, Takehisa Yamamoto, Geeta Hampson, Hiroyuki Koshiyama, Östen Ljunggren, Koichi Oba, In Myung Yang, Akimitsu Miyauchi, Michael J. Econs, Jeffrey Lavigne, Harald Jüppner

Research output: Contribution to journalArticle

661 Citations (Scopus)

Abstract

BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. METHODS: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [±SD] age, 48.4±19.6 years) and 26 healthy children (mean age, 10.9±5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0±13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9±17.2 years) were studied. RESULTS: Mean FGF-23 concentrations in the healthy adults and children were 55±50 and 69±36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481±528 RU per milliliter in those with suspected oncogenic osteomalacia and 353±510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. CONCLUSIONS: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.

Original languageEnglish (US)
Pages (from-to)1656-1663
Number of pages8
JournalNew England Journal of Medicine
Volume348
Issue number17
DOIs
StatePublished - Apr 24 2003

Fingerprint

Familial Hypophosphatemic Rickets
Phosphates
Amides
fibroblast growth factor 23
Oncogenic osteomalacia
Familial Hypophosphatemia
Hypophosphatemia
Endopeptidases
Mutation
Glutamine
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., ... Jüppner, H. (2003). Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New England Journal of Medicine, 348(17), 1656-1663. https://doi.org/10.1056/NEJMoa020881

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. / Jonsson, Kenneth B.; Zahradnik, Richard; Larsson, Tobias; White, Kenneth E.; Sugimoto, Toshitsugu; Imanishi, Yasuo; Yamamoto, Takehisa; Hampson, Geeta; Koshiyama, Hiroyuki; Ljunggren, Östen; Oba, Koichi; Yang, In Myung; Miyauchi, Akimitsu; Econs, Michael J.; Lavigne, Jeffrey; Jüppner, Harald.

In: New England Journal of Medicine, Vol. 348, No. 17, 24.04.2003, p. 1656-1663.

Research output: Contribution to journalArticle

Jonsson, KB, Zahradnik, R, Larsson, T, White, KE, Sugimoto, T, Imanishi, Y, Yamamoto, T, Hampson, G, Koshiyama, H, Ljunggren, Ö, Oba, K, Yang, IM, Miyauchi, A, Econs, MJ, Lavigne, J & Jüppner, H 2003, 'Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia', New England Journal of Medicine, vol. 348, no. 17, pp. 1656-1663. https://doi.org/10.1056/NEJMoa020881
Jonsson, Kenneth B. ; Zahradnik, Richard ; Larsson, Tobias ; White, Kenneth E. ; Sugimoto, Toshitsugu ; Imanishi, Yasuo ; Yamamoto, Takehisa ; Hampson, Geeta ; Koshiyama, Hiroyuki ; Ljunggren, Östen ; Oba, Koichi ; Yang, In Myung ; Miyauchi, Akimitsu ; Econs, Michael J. ; Lavigne, Jeffrey ; Jüppner, Harald. / Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. In: New England Journal of Medicine. 2003 ; Vol. 348, No. 17. pp. 1656-1663.
@article{d92904157cfa48f1a63993705995724f,
title = "Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia",
abstract = "BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. METHODS: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [±SD] age, 48.4±19.6 years) and 26 healthy children (mean age, 10.9±5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0±13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9±17.2 years) were studied. RESULTS: Mean FGF-23 concentrations in the healthy adults and children were 55±50 and 69±36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481±528 RU per milliliter in those with suspected oncogenic osteomalacia and 353±510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. CONCLUSIONS: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.",
author = "Jonsson, {Kenneth B.} and Richard Zahradnik and Tobias Larsson and White, {Kenneth E.} and Toshitsugu Sugimoto and Yasuo Imanishi and Takehisa Yamamoto and Geeta Hampson and Hiroyuki Koshiyama and {\"O}sten Ljunggren and Koichi Oba and Yang, {In Myung} and Akimitsu Miyauchi and Econs, {Michael J.} and Jeffrey Lavigne and Harald J{\"u}ppner",
year = "2003",
month = "4",
day = "24",
doi = "10.1056/NEJMoa020881",
language = "English (US)",
volume = "348",
pages = "1656--1663",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

AU - Jonsson, Kenneth B.

AU - Zahradnik, Richard

AU - Larsson, Tobias

AU - White, Kenneth E.

AU - Sugimoto, Toshitsugu

AU - Imanishi, Yasuo

AU - Yamamoto, Takehisa

AU - Hampson, Geeta

AU - Koshiyama, Hiroyuki

AU - Ljunggren, Östen

AU - Oba, Koichi

AU - Yang, In Myung

AU - Miyauchi, Akimitsu

AU - Econs, Michael J.

AU - Lavigne, Jeffrey

AU - Jüppner, Harald

PY - 2003/4/24

Y1 - 2003/4/24

N2 - BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. METHODS: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [±SD] age, 48.4±19.6 years) and 26 healthy children (mean age, 10.9±5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0±13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9±17.2 years) were studied. RESULTS: Mean FGF-23 concentrations in the healthy adults and children were 55±50 and 69±36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481±528 RU per milliliter in those with suspected oncogenic osteomalacia and 353±510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. CONCLUSIONS: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.

AB - BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. METHODS: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [±SD] age, 48.4±19.6 years) and 26 healthy children (mean age, 10.9±5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0±13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9±17.2 years) were studied. RESULTS: Mean FGF-23 concentrations in the healthy adults and children were 55±50 and 69±36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481±528 RU per milliliter in those with suspected oncogenic osteomalacia and 353±510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. CONCLUSIONS: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.

UR - http://www.scopus.com/inward/record.url?scp=20244368616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244368616&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa020881

DO - 10.1056/NEJMoa020881

M3 - Article

C2 - 12711740

AN - SCOPUS:20244368616

VL - 348

SP - 1656

EP - 1663

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -